4.89 0.03 (0.62%) | 07-26 16:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 6.58 | 1-year : | 7.69 |
Resists | First : | 5.63 | Second : | 6.58 |
Pivot price | 4.95 ![]() |
|||
Supports | First : | 3.86 | Second : | 2.75 |
MAs | MA(5) : | 5.16 ![]() |
MA(20) : | 4.45 ![]() |
MA(100) : | 3.63 ![]() |
MA(250) : | 2.9 ![]() |
|
MACD | MACD : | 0.4 ![]() |
Signal : | 0.4 ![]() |
%K %D | K(14,3) : | 71.9 ![]() |
D(3) : | 81.1 ![]() |
RSI | RSI(14): 58 ![]() |
|||
52-week | High : | 5.63 | Low : | 0.49 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MYO ] has closed above bottom band by 45.5%. Bollinger Bands are 20.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 5 - 5.02 | 5.02 - 5.04 |
Low: | 4.82 - 4.84 | 4.84 - 4.86 |
Close: | 4.85 - 4.88 | 4.88 - 4.92 |
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Fri, 26 Jul 2024
Myomo, Inc. (MYO): Hedge Funds Are Bullish on This Robotics Stock Now - Insider Monkey
Mon, 08 Jul 2024
Myomo Reports Preliminary Second Quarter 2024 Revenues and Operating Metrics - StockTitan
Mon, 08 Jul 2024
Myomo Reports Preliminary Second Quarter 2024 Revenues and Operating Metrics - Yahoo Finance
Sun, 30 Jun 2024
Myomo, Inc. (NYSEAMERICAN:MYO) Short Interest Up 24.8% in June - MarketBeat
Sat, 25 May 2024
Myomo: TAM Expansion Opportunity From Policy Tailwinds - Seeking Alpha
Fri, 17 May 2024
Insider Sale: Chief Medical Officer Harry Kovelman Sells 35,426 Shares of Myomo Inc (MYO) - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
AMEX
|
|
Sector:
Healthcare
|
|
Industry:
Medical - Devices
|
|
Shares Out | 27 (M) |
Shares Float | 15 (M) |
Held by Insiders | 13.8 (%) |
Held by Institutions | 47.9 (%) |
Shares Short | 236 (K) |
Shares Short P.Month | 298 (K) |
EPS | -0.5 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0.41 |
Profit Margin | -42.5 % |
Operating Margin | -39.9 % |
Return on Assets (ttm) | -34.4 % |
Return on Equity (ttm) | -83.4 % |
Qtrly Rev. Growth | 28 % |
Gross Profit (p.s.) | 0.38 |
Sales Per Share | 0.69 |
EBITDA (p.s.) | -0.3 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -6 (M) |
Levered Free Cash Flow | -3 (M) |
PE Ratio | -9.98 |
PEG Ratio | 35.1 |
Price to Book value | 11.64 |
Price to Sales | 6.99 |
Price to Cash Flow | -20.66 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |